Under a tenth of patients eligible to benefit from obesity jabs like Wegovy are able to get them, states the global health agency as it releases its initial advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our new guidelines acknowledges that obesity is a long-term condition that can be managed with thorough and continuous care," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant hurdles to broad availability to the injections that can help people shift significant body mass, notes the organization.
Skinny Jab Shortage
Even under the current best projected case, the supply of such drugs might only reach about 100 million people – under 10% of those who need them, according to the health organization.
The advice calls on nations and manufacturers to expand availability, through strategies like voluntary licensing.
The intellectual property rights on a key compound – the core component of the drug Wegovy – is due to expire in several countries in 2026.
The Way Obesity Drugs Work
These medications imitate a natural hormone to slow digestion, curb appetite and enhance the sense of being full so users consume fewer calories.
People usually start to lose weight after several weeks of starting on the regular doses.
Studies points to people may see weight return a year later of halting the medication, as their typical food cravings come back.
Being carrying excess weight elevates your chance for contracting diseases, including type 2 diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
